IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
IRADIMED CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$87.65−0.62 (-0.70%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 49.0
- Dividend yield
- –
Iradimed statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Iradimed | Industry median |
|---|---|---|
| Market Cap | $1.12B | $229.23M |
| Enterprise Value | $1.06B | $194.73M |
| PE Ratio | 48.97 | 33.41 |
| PS Ratio | 12.98 | 3.14 |
| PB Ratio | 11.02 | 3.19 |
| P/TBV Ratio | 11.40 | 4.69 |
| P/FCF Ratio | 44.62 | 27.25 |
| P/OCF Ratio | 41.30 | 22.23 |
Enterprise value
| Measure | Iradimed | Industry median |
|---|---|---|
| EV / Sales | 12.30 | 2.93 |
| EV / EBITDA | 36.38 | 19.97 |
| EV / EBIT | 38.53 | 25.47 |
| EV / FCF | 42.27 | 27.85 |
Income (trailing twelve months)
| Measure | Iradimed | Industry median |
|---|---|---|
| Revenue | $86.34M | $102.39M |
| Gross Profit | $65.50M | $60.36M |
| Operating Income | $27.56M | -$4.31M |
| Pretax Income | $29.75M | -$2.26M |
| Net Income | $23.05M | -$6.57M |
| EBITDA | $29.18M | -$1.98M |
| EPS (Diluted) | $1.79 | -$0.07 |
Margins
| Measure | Iradimed | Industry median |
|---|---|---|
| Gross Margin | 75.9% | 55.1% |
| Operating Margin | 31.9% | -6.04% |
| Pretax Margin | 34.5% | -4.11% |
| Profit Margin | 26.7% | -10.5% |
| EBITDA Margin | 33.8% | -2.67% |
| FCF Margin | 29.1% | -0.30% |
Returns
| Measure | Iradimed | Industry median |
|---|---|---|
| Return on Equity (ROE) | 23.5% | -19.2% |
| Return on Assets (ROA) | 20.8% | -13.3% |
| Return on Invested Capital (ROIC) | 50.9% | -4.11% |
| Return on Capital Employed (ROCE) | 26.0% | -9.07% |
Growth
| Measure | Iradimed | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 11.2% | 8.85% |
| Net Income Growth (YoY) | 11.6% | 10.6% |
| EPS Growth (YoY) | 10.5% | 10.6% |
| FCF Growth (YoY) | 76.8% | 10.6% |
| Revenue Growth (3Y CAGR) | 16.3% | 7.08% |
| Revenue Growth (5Y CAGR) | 21.5% | 11.8% |
| EPS Growth (3Y CAGR) | 19.7% | 3.06% |
| EPS Growth (5Y CAGR) | 73.9% | 7.64% |
Balance sheet
| Measure | Iradimed | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $59.08M | $37.33M |
| Net Cash (Debt) | $59.08M | $3.92M |
| Net Cash Per Share | $4.62 | $0.28 |
| Equity (Book Value) | $101.75M | $57.36M |
| Book Value Per Share | $7.96 | $2.81 |
| Tangible Book Value | $98.31M | $10.71M |
| Working Capital | $77.56M | $54.64M |
Financial position
| Measure | Iradimed | Industry median |
|---|---|---|
| Current Ratio | 9.46 | 2.50 |
| Quick Ratio | 7.89 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Iradimed | Industry median |
|---|---|---|
| Operating Cash Flow | $27.14M | -$653.46K |
| Capital Expenditures | -$2.02M | -$3.69M |
| Free Cash Flow | $25.12M | -$835.02K |
| FCF Per Share | $1.96 | -$0.02 |
Efficiency
| Measure | Iradimed | Industry median |
|---|---|---|
| Asset Turnover | 0.78 | 0.59 |
| Inventory Turnover | 1.78 | 2.21 |
| Revenue Per Employee | $520.11K | $322.75K |
| Profits Per Employee | $138.88K | -$52.11K |
| Employee Count | 166 | 197 |
Dividends and yields
| Measure | Iradimed | Industry median |
|---|---|---|
| Earnings Yield | 2.06% | -6.92% |
| FCF Yield | 2.24% | -0.62% |
| Payout Ratio | 68.7% | 30.3% |
| FCF Payout Ratio | 63.0% | 21.9% |
Shares
| Measure | Iradimed | Industry median |
|---|---|---|
| Shares Outstanding | 12,787,000 | 44,856,700 |
| Shares Change (YoY) | 0.40% | 3.35% |
| Shares Change (QoQ) | 0.03% | 0.27% |
| Float | 8,248,180 | 36,934,400 |
| Shares Held by Insiders | 35.5% | 10.6% |
| Shares Held by Institutions | 61.4% | 63.5% |
Taxes
| Measure | Iradimed | Industry median |
|---|---|---|
| Income Tax | $6.69M | $1.52M |
| Effective Tax Rate | 22.5% | 18.6% |
Scores
| Measure | Iradimed | Industry median |
|---|---|---|
| Graham Number | $17.90 | $34.37 |
| Graham Upside | -79.6% | -58.3% |
| Altman Z-Score | 54.05 | 1.95 |
| Piotroski F-Score | 6 | 5 |
| Beneish M-Score | -2.55 | -2.64 |
Calculated by StockData from Iradimed's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.